Professor Alan H.B. Wu: Contributions that will stand the test of time

IF 4.1 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2026-02-15 Epub Date: 2025-12-18 DOI:10.1016/j.cca.2025.120795

Robert H. Christenson , Pete Kavsak , Xander M.R. van Wijk

引用次数: 0

Abstract

This article honors Dr. Alan H.B. Wu's 25-year leadership as Editor-in-Chief of Clinica Chimica Acta and his transformative contributions to clinical chemistry and laboratory medicine. A central focus of his career has been advancing the use of cardiac biomarkers, particularly cardiac troponin (cTn) and natriuretic peptides, for the diagnosis and management of myocardial infarction and heart failure. Dr. Wu's studies helped establish the diagnostic and prognostic value of cTn, contributed to standardization and high-sensitivity assay development, and explored novel technologies. His work on biological variability emphasized the limitations of population-based reference intervals and promoted individualized interpretation of test results. Through guidelines and collaborations, Dr. Wu has shaped biomarker adoption, clinical practice, and laboratory quality standards. His vision of personalized laboratory medicine continues to advance diagnostics and improve patient care.

查看原文本刊更多论文

吴浩斌教授：经得起时间考验的贡献。

这篇文章是为了纪念Alan H.B. Wu博士25年来作为《临床化学学报》总编辑的领导地位，以及他对临床化学和实验室医学的变革性贡献。他职业生涯的中心焦点一直是推进心脏生物标志物的使用，特别是心肌肌钙蛋白（cTn）和利钠肽，用于心肌梗死和心力衰竭的诊断和管理。吴博士的研究帮助建立了cTn的诊断和预后价值，促进了标准化和高灵敏度检测的发展，并探索了新技术。他在生物变异方面的工作强调了基于人群的参考区间的局限性，并促进了对测试结果的个性化解释。通过指导和合作，吴博士塑造了生物标志物的采用、临床实践和实验室质量标准。他对个性化实验室医学的愿景继续推进诊断和改善患者护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.